Breast Cancer During Pregnancy: A Complete Guide to Diagnosis, Treatment, and Safety

Table of Contents

• Key Points
• What Is Pregnancy-Associated Breast Cancer?
• Why Breast Cancer During Pregnancy Is Uniquely Challenging
• Global Perspectives: Diagnostic Delays and Their Consequences
• How Breast Cancer Is Diagnosed During Pregnancy
• The Role of Multidisciplinary Specialist Teams
• Treatment Approaches: What Is Safe for Mother and Baby?
• Chemotherapy During Pregnancy: Timing and Safety
• Treatments Given After Delivery
• Fetal and Maternal Monitoring
• Planning for Delivery: Avoiding Early Birth
• Outcomes: How Do Pregnant Patients Fare Compared to Others?
• Limitations of This Review
• Recommendations for Patients and Families
• Frequently Asked Questions
• Source Information

Key Points

• Pregnancy-associated breast cancer includes cancer diagnosed during pregnancy or in the postpartum period; both need specialized coordinated care.
• Diagnostic delays are common because pregnancy breast changes can mask lumps, leading to later-stage diagnosis and worse outcomes.
• Ultrasound, mammography with abdominal shielding, and biopsy under local anesthesia are safe and essential for diagnosis during pregnancy.
• Anthracycline and taxane chemotherapy is safe after the first trimester, but must stop three weeks before delivery to reduce infection and bleeding risks.
• Avoid unnecessary early delivery: iatrogenic premature delivery harms the baby's cognitive development; stage-for-stage outcomes equal non-pregnant patients when treated appropriately.

What Is Pregnancy-Associated Breast Cancer?

Pregnancy-associated breast cancer (PABC) is a term that covers two distinct situations: breast cancer that is diagnosed during pregnancy (BCP) and breast cancer that is diagnosed in the postpartum period (PPBC) — meaning after the baby is born. Both present unique medical and emotional challenges, but breast cancer diagnosed during pregnancy is particularly complex because two lives are affected simultaneously.

This review, published by an international team of experts from India, the United Kingdom, and the United States, takes a comprehensive global view of how this condition is managed. The authors thoroughly reviewed published literature and real-world practices from around the world, including the first published data from an Indian patient registry. Their goal was to derive practical conclusions that can help optimize care for this rare and vulnerable patient population.

Why Breast Cancer During Pregnancy Is Uniquely Challenging

When a patient is diagnosed with breast cancer while pregnant, doctors must think about maternal safety (the health and survival of the mother) and fetal safety (the health of the developing baby) at the same time. Every diagnostic test, every treatment decision, and every medication must be weighed against its potential impact on the pregnancy.

This dual concern creates complexities that don't exist for non-pregnant patients. For example:

• Some imaging tests need to be modified or timed carefully to minimize radiation exposure to the fetus.
• Chemotherapy may be safe in the second and third trimesters but must be avoided in the first trimester.
• Some treatments — such as certain targeted therapies and hormone therapies — must be delayed until after delivery.
• The timing of delivery itself becomes a medical decision that affects both cancer treatment and the baby's brain development.

These complexities mean that a one-size-fits-all approach is not possible. Instead, treatment must be carefully tailored to each patient's individual circumstances, including the stage of the cancer, the type of breast cancer, and the trimester of pregnancy.

Global Perspectives: Diagnostic Delays and Their Consequences

One of the most important findings of this review is that diagnostic delays are common in pregnancy-associated breast cancer. These delays have serious consequences: they result in upstaging (the cancer being diagnosed at a more advanced stage than it would have been if found earlier) and ultimately lead to inferior outcomes for the patient.

Why do these delays happen? Several factors contribute:

• Normal pregnancy causes breast changes — swelling, tenderness, and enlargement — that can mask a breast lump or make it harder to notice.
• Both patients and healthcare providers may assume that breast symptoms are just a normal part of pregnancy.
• There may be hesitation to perform imaging or biopsy in a pregnant patient due to concerns about fetal safety, even though these procedures are generally safe when done properly.
• In low- and middle-income countries (LMICs), limited access to diagnostic tools and specialist care can compound these delays.

The authors emphasize that early detection is especially critical in low- and middle-income countries, where advanced disease at diagnosis is more common and treatment resources may be more limited.

How Breast Cancer Is Diagnosed During Pregnancy

When breast cancer is suspected during pregnancy, the review states that specific diagnostic steps are mandatory. The essential workup includes:

1. Sonography (ultrasound) and mammography: Ultrasound is a safe and useful first step. Mammography can also be performed during pregnancy with appropriate abdominal shielding to protect the fetus. The radiation exposure from a mammogram to the fetus is extremely low and considered safe.
2. Biopsy: A tissue sample of the suspicious area must be obtained for a definitive diagnosis. This is done under local anesthesia, which is safe during pregnancy.
3. Immunohistochemistry (IHC) for hormone receptors: The biopsy tissue must be tested for three critical markers:
   • Estrogen receptors (ER) — whether cancer cells are fueled by estrogen
   • Progesterone receptors (PR) — whether cancer cells are fueled by progesterone
   • HER-2/neu receptors — a protein that can promote cancer cell growth

These receptor tests are essential because they determine what type of breast cancer the patient has and which treatments are most likely to work. For example, HER-2-positive cancers can be treated with targeted therapies, while hormone receptor-positive cancers may respond to endocrine (hormone-blocking) therapy.

The Role of Multidisciplinary Specialist Teams

One of the review's strongest messages is that multidisciplinary specialist teams are critical for managing breast cancer during pregnancy. This is not a condition that should be handled by a single doctor working alone. Instead, care should be coordinated by a team that includes:

• Medical oncologists (cancer doctors who manage chemotherapy and systemic treatments)
• Surgical oncologists (surgeons who operate on breast cancer)
• Radiation oncologists (doctors who administer radiation therapy)
• Maternal-fetal medicine specialists (obstetricians who manage high-risk pregnancies)
• Neonatologists (doctors who care for newborns, especially those born prematurely)
• Pathologists and radiologists experienced in pregnancy-related cancer
• Psychosocial support professionals (counselors, social workers)

The treatment plan must be trimester-dependent, meaning it changes based on how far along the pregnancy is. A treatment that is safe in the second trimester may not be safe in the first, and decisions made early in pregnancy may need to be revised as the pregnancy progresses.

Treatment Approaches: What Is Safe for Mother and Baby?

The review states that, for both surgery and systemic (whole-body) treatments, the approach in pregnant patients is largely similar to that of non-pregnant women when matched by cancer stage. The key difference is timing: treatments are adjusted around the pregnancy to protect the developing fetus.

Surgical treatment: Surgery is generally considered safe during pregnancy. The type of surgery — breast-conserving surgery (lumpectomy) or mastectomy (removal of the whole breast) — depends on the stage of the cancer, the tumor size relative to the breast, and the patient's preferences. Lymph node evaluation can also be performed. The main consideration is that surgery is typically performed under careful anesthetic management to ensure safety for both mother and baby.

Systemic treatment: Systemic treatments (chemotherapy, targeted therapy, endocrine therapy) are given in a stage-wise manner, similar to how they would be given to a non-pregnant patient. However, the specific timing, drug choices, and sequences are modified based on the trimester.

Chemotherapy During Pregnancy: Timing and Safety

A central finding of this review is that anthracycline- and taxane-based chemotherapy is found to be safe after the first trimester. These are two major classes of chemotherapy drugs commonly used to treat breast cancer:

• Anthracyclines (such as doxorubicin or epirubicin) — these are some of the most effective drugs against breast cancer but must be carefully monitored for effects on the heart.
• Taxanes (such as paclitaxel or docetaxel) — these drugs work by interfering with cell division and are often used in sequence with anthracyclines.

The first trimester (weeks 1 through 12) is the period when the baby's organs are forming. This is when chemotherapy carries the highest risk of birth defects (teratogenicity). Therefore, chemotherapy is avoided in the first trimester and typically started in the second trimester (after week 12) once organ development is largely complete.

The review also emphasizes a crucial safety measure: chemotherapy should stop three weeks prior to delivery. This timing is intended to prevent complications around the time of birth, specifically:

• Peripartum infection: Chemotherapy can suppress the mother's immune system, increasing the risk of infection during or after delivery.
• Bleeding: Chemotherapy can lower blood cell counts (platelets), increasing the risk of bleeding during childbirth.

By stopping chemotherapy three weeks before the planned delivery date, the mother's blood counts have time to recover, making delivery safer for both her and the baby.

Treatments Given After Delivery

Some breast cancer treatments cannot be given during pregnancy at all and must be administered post-delivery. These include:

• Anti-HER-2 targeted therapy: Drugs such as trastuzumab (Herceptin) target the HER-2 protein on cancer cells. These drugs are associated with risks to fetal development, particularly affecting the fetal heart and kidneys, so they are withheld until after the baby is born.
• Endocrine (hormone) therapy: Drugs such as tamoxifen or aromatase inhibitors block the effects of estrogen on hormone-receptor-positive breast cancer cells. These are also contraindicated during pregnancy and breastfeeding and are therefore started after delivery.
• Radiation therapy: Radiation to the chest area is not safe during pregnancy due to the risk of exposing the fetus to radiation. It is delayed until after delivery. This is one reason why mastectomy may be preferred over breast-conserving surgery in some pregnant patients — breast-conserving surgery requires postoperative radiation, which cannot safely be given during pregnancy.

The review makes clear that these treatments, while delayed, are still essential parts of the overall treatment plan. The timing of delivery and the plan for postpartum treatment must be coordinated carefully to avoid unnecessary gaps in care.

Fetal and Maternal Monitoring

Because both the mother and the baby are at risk during pregnancy-associated breast cancer, frequent fetal and maternal monitoring is required throughout the pregnancy. This monitoring is designed to minimize complications and detect problems early so they can be addressed promptly.

Fetal monitoring typically includes regular ultrasound examinations to assess growth, amniotic fluid levels, and overall well-being, as well as fetal heart rate monitoring. The frequency of monitoring may increase if there are any concerns about growth restriction or other complications.

Maternal monitoring includes regular blood tests to check blood counts, assessment of the cancer's response to treatment, and monitoring for potential side effects of chemotherapy, such as heart damage from anthracyclines.

Close collaboration between the oncology team and the obstetrics team is essential to coordinate these monitoring schedules and to make timely decisions about treatment adjustments if problems arise.

Planning for Delivery: Avoiding Early Birth

One of the most important messages in this review is a warning against iatrogenic premature delivery — that is, delivering the baby early for medical reasons that are not truly necessary. The review states clearly that iatrogenic premature delivery leads to poor neurocognition (impaired brain development and cognitive function in the child) and should be avoided.

Premature babies are at higher risk for a range of health problems, including developmental delays, respiratory issues, and long-term cognitive difficulties. The authors emphasize that delivering a baby early is not a risk-free "solution" to the challenge of treating cancer during pregnancy. In many cases, it is safer to continue the pregnancy to term (or as close to term as safely possible) while managing the mother's cancer with trimester-appropriate treatments.

The decision about when to deliver must balance:

• The baby's need for continued development in the womb
• The mother's need for treatments that can only be given after delivery (such as HER-2 targeted therapy, endocrine therapy, or radiation)
• The need to stop chemotherapy three weeks before delivery to reduce infection and bleeding risks

This requires careful planning and coordination among the entire care team, and the plan should be re-evaluated regularly as the pregnancy progresses.

Outcomes: How Do Pregnant Patients Fare Compared to Others?

This is perhaps the most reassuring finding of the review: stage-wise outcomes for pregnant patients are similar to those of non-pregnant patients with breast cancer. In other words, when a pregnant patient's cancer is diagnosed at the same stage as a non-pregnant patient's cancer, and both receive appropriate treatment, the long-term survival outlook is comparable.

This underscores a critical point: the poor outcomes sometimes associated with pregnancy-associated breast cancer are largely driven by advanced stage at diagnosis, not by the pregnancy itself. Because diagnostic delays are common, many pregnant patients are diagnosed at later stages, and it is this upstaging that drives inferior outcomes — not any inherent biological difference or the fact that the patient is pregnant.

The authors conclude that improving outcomes in pregnancy-associated breast cancer requires a two-pronged approach:

1. Early detection: Increasing awareness among patients and clinicians that breast symptoms during pregnancy must be taken seriously and investigated promptly.
2. Appropriate treatment: Ensuring that pregnant patients receive stage-appropriate treatment from multidisciplinary specialist teams, just as non-pregnant patients do.

Limitations of This Review

As with any published review, there are limitations that patients should be aware of when interpreting these findings. First, this is a review article that synthesizes existing published literature and registry data rather than a single prospective clinical trial. The quality of the underlying studies varies, and some of the evidence in this field comes from relatively small case series rather than large randomized controlled trials.

Second, randomized controlled trials in pregnant patients are extremely difficult to conduct due to ethical considerations — researchers cannot randomly assign a pregnant patient to receive or not receive a treatment when fetal safety is at stake. As a result, much of the evidence in this field comes from observational data and real-world registries.

Third, the review notes that global data are uneven. The first Indian registry data are included, which is a valuable contribution, but data from many low- and middle-income countries remain sparse. Treatment practices may vary between regions, and findings from high-resource settings may not translate perfectly to settings with fewer resources.

Finally, because no specific numerical survival statistics or odds ratios were cited in this review abstract, patients should consult their own care team for individualized risk information based on their specific cancer stage, biology, and treatment plan.

Recommendations for Patients and Families

Based on this review, here are actionable recommendations for patients diagnosed with breast cancer during pregnancy and their families:

• Insist on timely evaluation of breast symptoms. If you notice a lump, skin change, or any unusual breast symptom during pregnancy, report it to your doctor immediately. Do not let anyone dismiss it as a "normal pregnancy change" without proper evaluation.
• Ensure a complete diagnostic workup. This should include ultrasound and mammography (with abdominal shielding), a biopsy, and immunohistochemistry testing for estrogen receptors, progesterone receptors, and HER-2/neu receptors. These results are essential for planning treatment.
• Seek care at a center with a multidisciplinary team. Look for a hospital that has experience managing cancer during pregnancy, with specialists in medical oncology, surgical oncology, radiation oncology, and maternal-fetal medicine who work together as a team.
• Ask about trimester-specific treatment planning. Your treatment plan should be designed around your stage of pregnancy. Chemotherapy can be safely given after the first trimester, while HER-2 targeted therapy, endocrine therapy, and radiation are typically delayed until after delivery.
• Confirm that chemotherapy timing is coordinated with delivery. If you are receiving chemotherapy, your care team should plan to stop it three weeks before your scheduled delivery to reduce the risk of infection and bleeding.
• Avoid unnecessary early delivery. Unless there is a clear medical reason, do not rush to deliver your baby prematurely. Early delivery can impact your child's cognitive development. Trust your care team to balance the timing of delivery with your cancer treatment needs.
• Stay informed about the encouraging outcomes. The evidence shows that, stage for stage, pregnant patients treated appropriately have outcomes similar to non-pregnant patients. Early detection and treatment are the best protection for both you and your baby.
• Advocate for global equity. If you live in a low- or middle-income country, know that early detection is especially important. Ask your providers about access to diagnostic tools and specialist care, and seek second opinions when possible.

The authors of this review also call for global collaborations to improve care for pregnancy-associated breast cancer worldwide. More data from diverse regions, shared treatment protocols, and international research partnerships are needed to continue improving outcomes.

Frequently Asked Questions

What is pregnancy-associated breast cancer?

Pregnancy-associated breast cancer covers two situations: breast cancer diagnosed during pregnancy, and breast cancer diagnosed in the postpartum period after the baby is born. Both create unique medical and emotional challenges, but a diagnosis during pregnancy is especially complex because it affects two lives at once, requiring careful balancing of maternal and fetal safety.

Why are breast cancers during pregnancy often found at a later stage?

Normal pregnancy breast changes like swelling and tenderness can hide a lump or make it harder to notice. Patients and doctors may assume symptoms are just normal pregnancy effects, and there can be hesitation to do imaging or biopsy out of concern for the baby, even though these are generally safe when done properly.

Are ultrasound, mammography, and biopsy safe during pregnancy?

Yes. Ultrasound is a safe first step, and mammography with abdominal shielding exposes the fetus to extremely low radiation that is considered safe. A biopsy under local anesthesia is also safe during pregnancy. The tissue sample must then be tested for estrogen, progesterone, and HER-2/neu receptors because these markers guide treatment choices.

Which breast cancer treatments can be given during pregnancy, and which ones must wait?

Surgery is generally safe during pregnancy with careful anesthesia. Chemotherapy with anthracyclines and taxanes is safe after the first trimester, but must stop three weeks before delivery. Anti-HER-2 targeted therapy, endocrine (hormone) therapy, and radiation are not safe during pregnancy and are delayed until after the baby is born.

Why does chemotherapy need to stop three weeks before delivery?

Chemotherapy can suppress the mother's immune system and lower blood cell counts. Stopping treatment three weeks before the planned delivery gives the mother's blood counts time to recover, which reduces the risk of peripartum infection and bleeding during or after childbirth for both mother and baby.

Should I have my baby early so I can start more cancer treatments?

No, in most cases early delivery should be avoided. Iatrogenic premature delivery leads to poor neurocognition, meaning impaired brain development and cognitive function in the child. The timing of delivery must balance the baby's need for development with the mother's need for treatments that can only be given after delivery, so trust your care team to plan carefully.

What are the long-term outcomes for pregnant breast cancer patients compared to non-pregnant patients?

When a pregnant patient is diagnosed at the same cancer stage as a non-pregnant patient and receives appropriate treatment, their long-term survival outlook is comparable. Poorer outcomes in pregnancy-associated breast cancer are mostly driven by later stage at diagnosis from delays, not by the pregnancy itself or any biological difference.

Could a second opinion change the treatment plan for breast cancer diagnosed during pregnancy?

Yes — because treatment for breast cancer during pregnancy is highly dependent on trimester and requires a multidisciplinary team. A second opinion can verify that chemotherapy is planned only after the first trimester and stopped three weeks before delivery, that surgery is timed safely, and that anti-HER-2 therapy, endocrine therapy, and radiation are deferred until after birth. It can also confirm that the diagnostic workup included biopsy and receptor testing. Stage-for-stage, appropriate treatment yields outcomes similar to non-pregnant patients, so a plan that follows these principles is critical. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Management of breast cancer diagnosed during pregnancy global perspectives - PubMed

Publication details: Expert Review of Anticancer Therapy. 2022 December; Volume 22, Issue 12, Pages 1301–1308. DOI: 10.1080/14737140.2022.2150167. PMID: 36480337.

This patient-friendly article is based on peer-reviewed research. It was written to help patients and families understand the findings of the original scientific review. It does not provide individual medical advice. Patients should discuss all treatment decisions with their healthcare team.